Physician profile
Britney Dann
NPI 1962753947
$13,786.88
in general payments reported to CMS, 2019-2025
37 companies · $3,489 in 2025
The $3,489 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,298 · 2022: $2,242 · 2023: $3,271 · 2024: $3,488 · 2025: $3,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,039.80 |
| Education | $207.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,914.14 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,777.16 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $1,521.97 | 2021-2025 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $1,018.86 | 2021-2025 | |
| Celgene Corporation | $831.21 | 2021-2024 | Zeposia |
| Genzyme Corporation | $704.50 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $512.96 | 2024-2025 | Zenpep |
| Celltrion USA INC. | $459.39 | 2024-2025 | Vegzelma, Zymfentra |
| Redhill Biopharma INC. | $350.48 | 2022-2024 | Talicia, Movantik, Aemcolo |
| Ardelyx, INC. | $344.87 | 2022-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $270.31 | 2021-2025 | Eohilia, Gattex |
| Qol Medical, LLC | $245.75 | 2021-2025 | Sucraid |
| Nestle Healthcare Nutrition INC. | $227.21 | 2021-2023 | |
| Lilly USA, LLC | $213.49 | 2024-2025 | Omvoh |
| Braintree Laboratories, INC. | $209.44 | 2022-2025 | Sutab, Suflave |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Britney Dann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.